Amir Elstein - Teva Pharmaceutical Vice Chairman of the Board

TEVA Stock  ILA 5,214  30.00  0.57%   

Chairman

Mr. Amir Elstein is Independent Director of the Company. Mr. Elstein rejoined the Board of Directors in 2009. From January 2014 to July 2014, he served as Vice Chairman of the Board of Directors of Teva. Mr. Elstein serves as Chairman of the Board of Tower Semiconductor Ltd., Chairman of the Board of Governors of the Jerusalem College of Engineering and Chairman of the Board of the Israel Democracy Institute. Mr. Elstein also serves as Chairman andor as a member of the board of directors of several academic, scientific, educational, social and cultural institutions. Mr. Elstein served as the Chairman of the Board of Directors of Israel Corporation from 2010 to 2013. From 2004 to 2008, Mr. Elstein was a member of Tevas senior management, where his most recent position was Executive Vice President, Global Pharmaceutical Resources. From 1995 to 2004, Mr. Elstein served on Tevas Board of Directors. Prior to joining Teva as an executive in 2004, Mr. Elstein held a number of executive positions at Intel Corporationrationration, most recently as General Manager of Intel Electronics Ltd., an Israeli subsidiary of Intel Corporationrationration. Mr. Elstein received a B.Sc. in physics and mathematics from the Hebrew University in Jerusalem, an M.Sc. in solid state physics from the Hebrew University and a diploma in senior business management from the Hebrew University. since 2014.
Age 63
Tenure 10 years
Phone(972) 3 914 8213
Webwww.tevapharm.com
Elstein’s leadership positions in various international corporations, including his experience as a chairman in international public companies and his service as an executive officer at Teva and other companies, provides global business management and pharmaceutical expertise.

Teva Pharmaceutical Management Efficiency

The company has return on total asset (ROA) of 0.0363 % which means that it generated a profit of $0.0363 on every $100 spent on assets. This is way below average. Similarly, it shows a return on equity (ROE) of (0.2414) %, meaning that it generated substantial loss on money invested by shareholders. Teva Pharmaceutical's management efficiency ratios could be used to measure how well Teva Pharmaceutical manages its routine affairs as well as how well it operates its assets and liabilities.
The company has accumulated 19.1 B in total debt with debt to equity ratio (D/E) of 2.26, implying the company greatly relies on financing operations through barrowing. Teva Pharmaceutical has a current ratio of 0.99, indicating that it has a negative working capital and may not be able to pay financial obligations in time and when they become due. Debt can assist Teva Pharmaceutical until it has trouble settling it off, either with new capital or with free cash flow. So, Teva Pharmaceutical's shareholders could walk away with nothing if the company can't fulfill its legal obligations to repay debt. However, a more frequent occurrence is when companies like Teva Pharmaceutical sell additional shares at bargain prices, diluting existing shareholders. Debt, in this case, can be an excellent and much better tool for Teva to invest in growth at high rates of return. When we think about Teva Pharmaceutical's use of debt, we should always consider it together with cash and equity.

Similar Executives

Found 9 records

CHAIRMAN Age

Gabriel LastDelek Group
70
Shaul ElovitchBezeq Israeli Telecommunication
69
Shlomo ZoharB Communications
66
Eduardo ElsztainDiscount Investment Corp
58
Shaul ElovitchB Communications
69
Aviram WertheimAlony Hetz Properties
59
Menachem EinanAzrieli Group
78
Danna HakimAzrieli Group
50
Dana HakimAzrieli Group
47
Teva Pharmaceutical Industries Limited, a pharmaceutical company, develops, manufactures, markets, and distributes generic medicines, specialty medicines, and biopharmaceutical products in North America, Europe, and internationally. The company was founded in 1901 and is based in Tel Aviv-Yafo, Israel. TEVA PHARMA is traded on Tel Aviv Stock Exchange in Israel. Teva Pharmaceutical Industries (TEVA) is traded on Tel Aviv Stock Exchange in Israel and employs 34,004 people.

Management Performance

Teva Pharmaceutical Leadership Team

Elected by the shareholders, the Teva Pharmaceutical's board of directors comprises two types of representatives: Teva Pharmaceutical inside directors who are chosen from within the company, and outside directors, selected externally and held independent of Teva. The board's role is to monitor Teva Pharmaceutical's management team and ensure that shareholders' interests are well served. Teva Pharmaceutical's inside directors are responsible for reviewing and approving budgets prepared by upper management to implement core corporate initiatives and projects. On the other hand, Teva Pharmaceutical's outside directors are responsible for providing unbiased perspectives on the board's policies.
Moshe Many, Independent Director
Richard Daniell, Executive Vice President - European Commercial
Mark Sabag, Executive Vice President, Chief Human Resources Officer and Global Communications and Brand
Ronit SatchiFainaro, Independent Director
Richard Lerner, Independent Director
Galia Maor, Independent Director
Janet Vergis, Independent Director
Carlo Notaristefani, CEO of Global Operations and President of Global Operations
JeanMichel Halfon, Statutory - independent director
Eli Shani, Ex Portfolio
Dipankar Bhattacharjee, Senior Vice President CFO Americas and Head of Finance Operations
Abbas Hussain, Independent Director
Yitzhak Peterburg, Director
Hafrun Fridriksdottir, Executive Vice President and Presidentident of Global Generics R&D
Perry Nisen, Independent Director
Isaac Abravanel, Group Executive Vice President Teva Corporate in Israel and Global Community Alliances, Director
David Stark, Executive Vice President, Chief Legal Officer
Amir Elstein, Vice Chairman of the Board
Dan Suesskind, Director
Arie Belldegrun, Independent Director
Richard Egosi, Chief Legal Officer and Group Executive VP
Andrew Weil, Chief Accounting Officer
Jean Halfon, Statutory - independent director
Sven Dethlefs, Executive Vice President - Global Marketing & Portfolio
Robert Koremans, President CEO-Global Specialty Medicines
Gerald Lieberman, Independent Director
Roberto Mignone, Independent Director
Rosemary Crane, Independent Director
Nechemia Peres, Independent Director
Roger Abravanel, Independent Director
Eyal Desheh, CFO and Group Executive VP
Gianfranco Nazzi, Executive Vice President - International Markets Commercial
Kare Schultz, CEO Pres
Iris BeckCodner, Group Executive Vice President - Corporate Marketing Excellence and Communication
Amir Weiss, VP Officer
Brendan OGrady, Executive Vice President - North America Commercial
Michael Hayden, President - Global Research and Development, Chief Scientific Officer
Gabrielle Sulzberger, Statutory Independent Director
Eric Drape, Executive Vice President - Global Operations
Erez Vigodman, CEO and President Director and Member of Fin. and Invesment Committee
Eliyahu Kalif, Chief Financial Officer, Executive Vice President, Director
Kathleen Veit, Global VP
Joseph Nitzani, Independent Director
Deborah Griffin, Chief Accounting Officer
Timothy Wright, Head - Business Development, Strategy and Innovation
Sigurdur Olafsson, President and CEO - Global Generic Medicines Group
Murray Goldberg, Independent Director
Dan Propper, Independent Director
Ory Slonim, Independent Director
Michael McClellan, Chief Financial Officer, Executive Vice President
Kevin Mannix, Vice President Head of Investor Relations
Kaare Schultz, President, Chief Executive Officer, Director
Sol Barer, Independent Chairman of the Board
Eli Kalif, Chief Financial Officer, Executive Vice President, Director

Teva Stock Performance Indicators

The ability to make a profit is the ultimate goal of any investor. But to identify the right stock is not an easy task. Is Teva Pharmaceutical a good investment? Although profit is still the single most important financial element of any organization, multiple performance indicators can help investors identify the equity that they will appreciate over time.

Currently Active Assets on Macroaxis

Check out World Market Map to better understand how to build diversified portfolios, which includes a position in Teva Pharmaceutical Industries. Also, note that the market value of any company could be tightly coupled with the direction of predictive economic indicators such as signals in board of governors.
You can also try the USA ETFs module to find actively traded Exchange Traded Funds (ETF) in USA.

Complementary Tools for Teva Stock analysis

When running Teva Pharmaceutical's price analysis, check to measure Teva Pharmaceutical's market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Teva Pharmaceutical is operating at the current time. Most of Teva Pharmaceutical's value examination focuses on studying past and present price action to predict the probability of Teva Pharmaceutical's future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Teva Pharmaceutical's price. Additionally, you may evaluate how the addition of Teva Pharmaceutical to your portfolios can decrease your overall portfolio volatility.
Sign In To Macroaxis
Sign in to explore Macroaxis' wealth optimization platform and fintech modules
Cryptocurrency Center
Build and monitor diversified portfolio of extremely risky digital assets and cryptocurrency
Idea Optimizer
Use advanced portfolio builder with pre-computed micro ideas to build optimal portfolio
Risk-Return Analysis
View associations between returns expected from investment and the risk you assume
Fundamentals Comparison
Compare fundamentals across multiple equities to find investing opportunities
Portfolio Anywhere
Track or share privately all of your investments from the convenience of any device
Financial Widgets
Easily integrated Macroaxis content with over 30 different plug-and-play financial widgets
Please note, there is a significant difference between Teva Pharmaceutical's value and its price as these two are different measures arrived at by different means. Investors typically determine if Teva Pharmaceutical is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, Teva Pharmaceutical's price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.